Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People with Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV

Standard

In: Journal of infectious diseases, Vol. 225, No. 11, 01.06.2022, p. 1937-1947.

Research output: Contribution to journal › Article › Academic › peer-review

BibTeX

@article{37d3fc00d514459db025c675f005099f,

title = "Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People with Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV",

abstract = "Background: Within the ongoing AGEhIV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between human immunodeficiency virus (HIV)-positive and HIV-negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups. Methods: Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed every 6 months for incident SARS-CoV-2 infection, using combined immunoglobulin (Ig) A/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from 27 February 2020 through 30 April 2021, using complementary log-log regression. In those with incident SARS-CoV-2 infection, nucleocapsid (N) antibody levels were compared between groups using linear regression. Results: The study included 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGEhIV participants. The cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (P=.61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N antibody levels. Conclusions: HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar SARS-CoV-2 N antibody levels after infection compared with a comparable HIV-negative cohort. Clinical Trial Registration: NCT01466582.",

keywords = "COVID-19, HIV, SARS-CoV-2, incidence, serology",

author = "Verburgh, {Myrthe L.} and Anders Boyd and Wit, {Ferdinand W. N. M.} and {Schim van der Loeff}, {Maarten F.} and {van der Valk}, Marc and Margreet Bakker and Kootstra, {Neeltje A.} and {van der Hoek}, Lia and Peter Reiss",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2022",

month = jun,

day = "1",

doi = "10.1093/infdis/jiab616",

language = "English",

volume = "225",

pages = "1937--1947",

journal = "Journal of infectious diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "11",

}

RIS

TY - JOUR

T1 - Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People with Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV

AU - Verburgh, Myrthe L.

AU - Boyd, Anders

AU - Wit, Ferdinand W. N. M.

AU - Schim van der Loeff, Maarten F.

AU - van der Valk, Marc

AU - Bakker, Margreet

AU - Kootstra, Neeltje A.

AU - van der Hoek, Lia

AU - Reiss, Peter

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Background: Within the ongoing AGEhIV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between human immunodeficiency virus (HIV)-positive and HIV-negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups. Methods: Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed every 6 months for incident SARS-CoV-2 infection, using combined immunoglobulin (Ig) A/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from 27 February 2020 through 30 April 2021, using complementary log-log regression. In those with incident SARS-CoV-2 infection, nucleocapsid (N) antibody levels were compared between groups using linear regression. Results: The study included 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGEhIV participants. The cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (P=.61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N antibody levels. Conclusions: HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar SARS-CoV-2 N antibody levels after infection compared with a comparable HIV-negative cohort. Clinical Trial Registration: NCT01466582.

AB - Background: Within the ongoing AGEhIV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between human immunodeficiency virus (HIV)-positive and HIV-negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups. Methods: Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed every 6 months for incident SARS-CoV-2 infection, using combined immunoglobulin (Ig) A/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from 27 February 2020 through 30 April 2021, using complementary log-log regression. In those with incident SARS-CoV-2 infection, nucleocapsid (N) antibody levels were compared between groups using linear regression. Results: The study included 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGEhIV participants. The cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (P=.61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N antibody levels. Conclusions: HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar SARS-CoV-2 N antibody levels after infection compared with a comparable HIV-negative cohort. Clinical Trial Registration: NCT01466582.

KW - COVID-19

KW - HIV

KW - SARS-CoV-2

KW - incidence

KW - serology

UR - http://www.scopus.com/inward/record.url?scp=85126704100&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiab616

DO - 10.1093/infdis/jiab616

M3 - Article

C2 - 34929034

VL - 225

SP - 1937

EP - 1947

JO - Journal of infectious diseases

JF - Journal of infectious diseases

SN - 0022-1899

IS - 11

ER -

ID: 20989497

Generic Portal